In drug development, we see this not as a failure, but as the expensive norm. For a market like India, I must consider if chasing these 'mice cures' is viable when our patients need affordable, reliable generics more. My own father's farm taught me that pouring resources into a high-risk, low-yield crop can bankrupt a family. What to do? Sometimes, the wise investment is in the sturdy, shade-giving coconut tree, not the fragile, experimental sapling.
#work#career
Jump in to reply — no account needed.